Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)

• Company Description    Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States. Number of Employees: 141

• Price / Volume Information    Yesterday's Closing Price: $14.79 Daily Weekly Monthly 20 Day Moving Average: 982,427 shares Shares Outstanding: 51.72 (millions) Market Capitalization: $765.00 (millions) Beta: 2.20 52 Week High: $69.12 52 Week Low: $13.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -56.35% -52.20% 12 Week -63.09% -58.52% Year To Date -76.71% -71.54%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 Arsenal Yards Blvd. Suite 230 - Watertown,MA 02472 USA ph: 857-285-5300 fax: - investors@kymeratx.com http://www.kymeratx.com

• General Corporate Information    Officers Nello Mainolfi - Chief Executive Officer and Presdent Bruce Booth - Chairman Bruce Jacobs - Chief Financial Officer Jeff Albers - Director Pamela Esposito - Director Peer Information Kymera Therapeutics, Inc. (CORR.) Kymera Therapeutics, Inc. (RSPI) Kymera Therapeutics, Inc. (CGXP) Kymera Therapeutics, Inc. (BGEN) Kymera Therapeutics, Inc. (GTBP) Kymera Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501575104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/05/22 Share - Related Items Shares Outstanding: 51.72 Most Recent Split Date: (:1) Beta: 2.20 Market Capitalization: $765.00 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.58 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 5.20% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.78 Price/Cash Flow: - Price / Sales: 12.00 EPS Growth vs. Year Ago Period: -144.83% vs. Previous Quarter: -7.58% Sales Growth vs. Year Ago Period: -48.55% vs. Previous Quarter: -37.01% ROE 03/31/22 - -30.40 12/31/21 - -27.16 09/30/21 - -24.30 ROA 03/31/22 - -22.06 12/31/21 - -18.67 09/30/21 - -15.58 Current Ratio 03/31/22 - 4.88 12/31/21 - 4.88 09/30/21 - 5.75 Quick Ratio 03/31/22 - 4.88 12/31/21 - 4.88 09/30/21 - 5.75 Operating Margin 03/31/22 - -194.23 12/31/21 - -137.60 09/30/21 - -112.31 Net Margin 03/31/22 - -194.23 12/31/21 - -137.60 09/30/21 - -112.31 Pre-Tax Margin 03/31/22 - -194.23 12/31/21 - -137.60 09/30/21 - -112.31 Book Value 03/31/22 - 8.29 12/31/21 - 8.94 09/30/21 - 9.40 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.22 12/31/21 - 0.25 09/30/21 - 0.28

Powered by Zacks Investment Research ©